ORMP Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
-100.0%
2.0M
Cost of Revenue
0
0
0
0
-100.0%
2.0M
Gross Profit
0
0
0
0
-100.0%
13.0K
Operating Expenses
3.7M
-35.5%
5.7M
+133.7%
2.4M
-2.5%
2.5M
-44.8%
4.5M
R&D
1.6M
-19.8%
2.0M
+72.4%
1.2M
+11.5%
1.0M
-53.1%
2.2M
SG&A
2.1M
-43.9%
3.7M
+189.2%
1.3M
-12.4%
1.5M
-36.9%
2.3M
Operating Income
-3659000
+35.5%
-5672000
-133.7%
-2427000
+2.5%
-2489000
+44.7%
-4500000
EBITDA
-3629000
+35.7%
-5642000
-135.5%
-2396000
+2.6%
-2459000
+45.0%
-4470000
Net Income
38.3M
+282.8%
10.0M
-79.3%
48.4M
+264.9%
13.3M
+273.5%
-7642000
EPS (Basic)
$0.94
+308.7%
$0.23
-80.2%
$1.16
+262.5%
$0.32
+268.4%
$-0.19
EPS (Diluted)
$0.91
+333.3%
$0.21
-81.4%
$1.13
+264.5%
$0.31
+263.2%
$-0.19
Shares (Diluted)
42.0M
-2.5%
43.1M
+0.7%
42.8M
+0.4%
42.6M
+3.3%
41.2M
Oramed Pharmaceuticals (ORMP) โ€” Financials